.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB16_PeginterferonAlfacon2.PeginterferonAlfacon2 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AB16_PeginterferonAlfacon2.PeginterferonAlfacon2| name: | PeginterferonAlfacon2 |
| ATC code: | L03AB16 | route: | subcutaneous |
| n-compartments | 1 |
Peginterferon alfacon-2 is a synthetic, pegylated form of interferon alpha used as an antiviral and immunomodulatory agent, primarily developed for the treatment of chronic hepatitis C infection. Its clinical use has largely been replaced by direct acting antivirals, but it was previously approved as part of combination therapy for hepatitis C.
No published literature reporting specific pharmacokinetic parameters such as clearance, volume of distribution, or absorption rate constants for peginterferon alfacon-2 in humans could be identified. Approximate estimates have been suggested based on available information for similar pegylated interferons.
Hu, X, et al., & Werneburg, B (2016). COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects. British journal of clinical pharmacology 82(2) 380–388. DOI:10.1111/bcp.12968 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27060836
Xu, C, et al., & Sniukiene, V (2013). Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C. European journal of clinical pharmacology 69(12) 2045–2054. DOI:10.1007/s00228-013-1574-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23975236
Zhao, Y, et al., & Butts, CL (2022). Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study. Med (New York, N.Y.) 3(9) 612–621.e3. DOI:10.1016/j.medj.2022.06.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35853458